AA
ADAP

ALPS Advisors’s Adaptimmune Therapeutics ADAP Stock Holding History

ALPS Advisors’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-88,339
Closed -$95K – 1022
2022
Q3 		$95K Sell
88,339
-7,771
-8% -$14.3K ﹤0.01% 1033
2022
Q2 		$163K Buy
+96,110
New +$165K ﹤0.01% 1005
2021
Q4 		– Sell
-190,550
Closed -$985K – 890
2021
Q3 		$985K Sell
190,550
-14,225
-7% -$63.8K 0.01% 390
2021
Q2 		$872K Sell
204,775
-75,040
-27% -$364K 0.01% 419
2021
Q1 		$1.49M Buy
279,815
+265
+0.1% +$1.52K 0.01% 350
2020
Q4 		$1.51M Buy
279,550
+82,380
+42% +$448K 0.02% 346
2020
Q3 		$1.57M Sell
197,170
-8,278
-4% -$72.4K 0.02% 264
2020
Q2 		$2.06M Buy
+205,448
New +$1.29M 0.03% 234
2018
Q2 		– Sell
-125,655
Closed -$1.41M – 926
2018
Q1 		$1.41M Buy
125,655
+21,839
+21% +$191K 0.01% 256
2017
Q4 		$693K Buy
103,816
+11,716
+13% +$90.5K ﹤0.01% 330
2017
Q3 		$754K Buy
92,100
+28,208
+44% +$176K 0.01% 296
2017
Q2 		$287K Buy
63,892
+2,996
+5% +$15.7K ﹤0.01% 724
2017
Q1 		$336K Sell
60,896
-7,128
-10% -$31.2K ﹤0.01% 676
2016
Q4 		$275K Buy
+68,024
New +$326K ﹤0.01% 676

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

ALPS Advisors's ADAP Position: Q4 2022 in Review

ALPS Advisors sold out of Adaptimmune Therapeutics (ADAP) in Q4 2022, closing a stake of 88,339 shares — an estimated $95K sold.

ALPS Advisors first reported a position in ADAP in Q4 2016 and held it in 14 quarters. The position peaked at $2.06M in Q2 2020. 69 funds tracked by Wall St. Rank hold ADAP as of Q4 2022.

  • ALPS Advisors reported no remaining Adaptimmune Therapeutics position as of Q4 2022 after selling out during the quarter.
  • ALPS Advisors sold 88,339 Adaptimmune Therapeutics shares in Q4 2022, an estimated $95K.
  • ALPS Advisors first reported a position in Adaptimmune Therapeutics in Q4 2016 and held it in 14 quarters.
  • ALPS Advisors's Adaptimmune Therapeutics position peaked at $2.06M in Q2 2020.
  • 69 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2022.

Based on ALPS Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.